Epoprostenol Therapy for a Pediatric Patient With Subacute Heparin-Induced Thrombocytopenia and a Ventricular Assist Device Undergoing Heart Transplant: A Case Report

A A Pract. 2018 Dec 15;11(12):329-331. doi: 10.1213/XAA.0000000000000818.

Abstract

Concerns remain regarding the use of direct thrombin inhibitors for cardiopulmonary bypass anticoagulation in pediatric patients with heparin-induced thrombocytopenia undergoing complex cardiac surgery. We describe the safe and effective use of epoprostenol sodium as an alternative therapy before heparin exposure for a pediatric patient with subacute heparin-induced thrombocytopenia and a ventricular assist device undergoing heart transplant.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Cardiopulmonary Bypass
  • Combined Modality Therapy
  • Epoprostenol / administration & dosage*
  • Epoprostenol / therapeutic use
  • Heart Failure / therapy*
  • Heart Transplantation
  • Heart-Assist Devices
  • Heparin / adverse effects*
  • Humans
  • Male
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / therapy*
  • Treatment Outcome

Substances

  • Heparin
  • Epoprostenol